BellRing Brands 株価情報 (NYSE: BRBR)

最新ニュース BellRing Brands (NYSE:BRBR) 株価情報

BellRing Brands

BellRing Brands Inc is a United States-based company engaged in providing nutrition-related products. Its brands, Premier Protein, Dymatize, and PowerBar provides various products including ready-to-drink protein shakes, powders and nutrition bars. The company's products are distributed through a diverse network of channels including club, food, drug and mass, eCommerce, convenience and specialty.

BellRing Brands Inc

<ul>
<li>Global financial institution becomes the latest Official Partner of the new 32-team FIFA Club World Cup&#x2122;</li>
<li>Expanded partnership between Bank of America and FIFA supports the pursuit of excellence and achievement in football through two iconic sporting events</li>
<li>Bank of America will engage with billions of passionate football fans around the world, in order to deepen client relationships, engage local communities, and help drive growth throughout the USA and the major markets hosting FIFA Club World Cup 2025&#x2122; and FIFA World Cup 26&#x2122; matches</li>
</ul>
CHARLOTTE, N.C., Dec. 3, 2024 /PRNewswire/ -- FIFA is proud to announce Bank of America as the latest Official Partner of the FIFA Club World Cup 2025&#x2122;, the new tournament that will bring together 32 of the world's best clubs in the United States next year for the greatest global club competition in history.

News

Bank Of America To Become Official Partner Of FIFA Club World Cup 2025

Across the recent three months, 13 analysts have shared their insights on Clearwater Analytics Hldg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWAN#NYSE">CWAN</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">8</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $31.23, along with a high estimate of $40.00 and a low estimate of $22.00. This current average has increased by 19.75% from the previous average price target of $26.08. 
<img src="https://www.benzinga.com/files/images/story/2024/1733252491_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Clearwater Analytics Hldg among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Schwartz</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$40.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Rishi Jaluria</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$36.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Peter Heckmann</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Neutral</td>
<td>$35.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Brian Schwartz</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$35.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Rishi Jaluria</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$32.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Gabriela Borges</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Sell</td>
<td>$22.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Michael Turrin</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$33.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Alexei Gogolev</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$33.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Arvind Ramnani</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$28.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>James Faucette</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$30.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Brian Schwartz</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$31.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Rishi Jaluria</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$28.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Arvind Ramnani</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$23.00</td>
<td>$23.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Clearwater Analytics Hldg. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Clearwater Analytics Hldg compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Clearwater Analytics Hldg's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Clearwater Analytics Hldg's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CWAN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Clearwater Analytics Hldg analyst ratings.</a>
<h2>All You Need to Know About Clearwater Analytics Hldg</h2>
Clearwater Analytics Holdings Inc provides a SaaS solution for automated investment data aggregation, reconciliation, accounting and reporting services to insurers, investment managers, corporations, institutional investors and government entities. It earns revenue from providing access to its SaaS platform to customers, services that support the implementation on the SaaS platform, selling perpetual and term-based software licenses and providing maintenance and support and professional services under contracts with customers. The majority of the revenue is earned in the United States.
<h3>Clearwater Analytics Hldg: Delving into Financials</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Clearwater Analytics Hldg's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 22.36%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: Clearwater Analytics Hldg's net margin is impressive, surpassing industry averages. With a net margin of 3.13%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Clearwater Analytics Hldg's ROE stands out, surpassing industry averages. With an impressive ROE of 0.93%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.6%, the company showcases effective utilization of assets.
Debt Management: Clearwater Analytics Hldg's debt-to-equity ratio is below the industry average at 0.18, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

CWAN

Unveiling 13 Analyst Insights On Clearwater Analytics Hldg

Zscaler (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) underwent analysis by 23 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">7</td>
<td align="right">13</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">3</td>
<td align="right">8</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $228.91, along with a high estimate of $270.00 and a low estimate of $180.00. Witnessing a positive shift, the current average has risen by 3.67% from the previous average price target of $220.81.
<img src="https://www.benzinga.com/files/images/story/2024/1733252481_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The perception of Zscaler by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rob Owens</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$235.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Yun Kim</td>
<td>Loop Capital</td>
<td>Lowers</td>
<td>Hold</td>
<td>$195.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Keith Bachman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$222.00</td>
<td>$197.00</td>
</tr>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$230.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Ittai Kidron</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$250.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Eric Heath</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$250.00</td>
<td>$245.00</td>
</tr>
<tr>
<td>Patrick Colville</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$205.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Trevor Walsh</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$240.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Shyam Patil</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$225.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Hamza Fodderwala</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$205.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Patrick Colville</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$225.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Kingsley Crane</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$230.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Mike Cikos</td>
<td>Needham</td>
<td>Announces</td>
<td>Buy</td>
<td>$240.00</td>
<td>-</td>
</tr>
<tr>
<td>Brian Essex</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$240.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Gray Powell</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$238.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Joseph Gallo</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$245.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Eric Heath</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$245.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Saket Kalia</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$220.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Adam Borg</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$235.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Trevor Walsh</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$270.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Andrew DeGasperi</td>
<td>Exane BNP Paribas</td>
<td>Announces</td>
<td>Neutral</td>
<td>$180.00</td>
<td>-</td>
</tr>
<tr>
<td>Fatima Boolani</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$230.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Shyam Patil</td>
<td>Susquehanna</td>
<td>Maintains</td>
<td>Positive</td>
<td>$210.00</td>
<td>$210.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Zscaler. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Zscaler compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Zscaler's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Zscaler's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ZS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Zscaler analyst ratings.</a>
<h2>About Zscaler</h2>
Zscaler is a software-as-a-service, or SaaS, firm focusing on providing cloud-native cybersecurity solutions to primarily enterprise customers. Zscaler's offerings can be broadly partitioned into Zscaler Internet Access, which provides secure access to external applications, and Zscaler Private Access, which provides secure access to internal applications. The firm is headquartered in San Jose, California, and went public in 2018.
<h3>Financial Insights: Zscaler</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Zscaler displayed positive results in 3 months. As of 31 July, 2024, the company achieved a solid revenue growth rate of approximately 30.3%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -2.51%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -1.26%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Zscaler's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -0.33%, the company showcases efficient use of assets and strong financial health.
Debt Management: Zscaler's debt-to-equity ratio is below the industry average at 0.97, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>What Are Analyst Ratings?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: Zscaler In The Eyes Of 23 Experts

Analysts' ratings for Agilysys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGYS#NASDAQ">AGYS</a>) over the last quarter vary from bullish to bearish, as provided by 8 analysts.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $135.12, a high estimate of $150.00, and a low estimate of $124.00. This current average has increased by 8.31% from the previous average price target of $124.75. 
<img src="https://www.benzinga.com/files/images/story/2024/1733252451_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A clear picture of Agilysys's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Schwartz</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$150.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Mayank Tandon</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$145.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Brian Schwartz</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$135.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Nehal Chokshi</td>
<td>Northland Capital Markets</td>
<td>Raises</td>
<td>Outperform</td>
<td>$145.00</td>
<td>$132.00</td>
</tr>
<tr>
<td>Matthew Vanvliet</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$124.00</td>
<td>$118.00</td>
</tr>
<tr>
<td>Mayank Tandon</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$125.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Nehal Chokshi</td>
<td>Northland Capital Markets</td>
<td>Raises</td>
<td>Outperform</td>
<td>$132.00</td>
<td>$118.00</td>
</tr>
<tr>
<td>Mayank Tandon</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$125.00</td>
<td>$125.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Agilysys. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Agilysys compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Agilysys's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Agilysys's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/AGYS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Agilysys analyst ratings.</a>
<h2>All You Need to Know About Agilysys</h2>
Agilysys Inc has been a leader in hospitality software, delivering innovative cloud-native SaaS and on-premise solutions for hotels, resorts and cruise lines, casinos, corporate food service management, restaurants, universities, stadiums, and healthcare. The Company's software solutions include point-of-sale (POS), property management (PMS), inventory and procurement, payments, and related applications that manage and enhance the entire guest journey. Agilysys also is known for its world-class customer-centric service.
<h3>Agilysys's Economic Impact: An Analysis</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Over the 3 months period, Agilysys showcased positive performance, achieving a revenue growth rate of 16.49% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Agilysys's net margin excels beyond industry benchmarks, reaching 2.0%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Agilysys's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.53% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Agilysys's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.34% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Agilysys's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.28.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AGYS

Demystifying Agilysys: Insights From 8 Analyst Reviews

In the last three months, 18 analysts have published ratings on Maplebear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CART#NASDAQ">CART</a>), offering a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">11</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">8</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $49.56, a high estimate of $60.00, and a low estimate of $37.00. This current average reflects an increase of 6.06% from the previous average price target of $46.73. 
<img src="https://www.benzinga.com/files/images/story/2024/1733252436_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of Maplebear among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lee Horowitz</td>
<td>Deutsche Bank</td>
<td>Announces</td>
<td>Hold</td>
<td>$37.00</td>
<td>-</td>
</tr>
<tr>
<td>Ross Compton</td>
<td>Macquarie</td>
<td>Raises</td>
<td>Outperform</td>
<td>$52.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Jason Helfstein</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$60.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Andrew Boone</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$51.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Thomas Champion</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$58.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Ross Sandler</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$56.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Doug Anmuth</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$52.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Justin Post</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$51.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Brian Pitz</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$48.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Colin Sebastian</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$51.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Jason Helfstein</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$55.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Mark Kelley</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$55.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>John Colantuoni</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Hold</td>
<td>$45.00</td>
<td>-</td>
</tr>
<tr>
<td>Deepak Mathivanan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$45.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Justin Post</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$45.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Brian Nowak</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$41.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Deepak Mathivanan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$45.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Deepak Mathivanan</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Overweight</td>
<td>$45.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Maplebear. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Maplebear compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Maplebear's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into Maplebear's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CART/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Maplebear analyst ratings.</a>
<h2>All You Need to Know About Maplebear</h2>
Maplebear (Instacart) operates a leading grocery delivery platform in the United States and Canada. The company partners with various regional and national grocers, which offer their selection of food and other goods to customers through Instacart's ubiquitous platform. Once an item is ordered through Instacart's site, the item is picked and delivered to the customer's home by one of the platform's 600,000 shoppers, who are classified as independent contractors. Instacart earns fees based on average order value and leverages its platform's high usage to sell advertising, mainly to consumer-packaged goods companies. Instacart currently has about 8 million monthly active users (or orderers) on its platform.
<h3>Maplebear's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Maplebear's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 11.52%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Staples sector.
Net Margin: Maplebear's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 13.61% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Maplebear's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.92% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Maplebear's ROA excels beyond industry benchmarks, reaching 2.92%. This signifies efficient management of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.01, Maplebear adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CART

Key Takeaways From Maplebear Analyst Ratings

In the preceding three months, 8 analysts have released ratings for Interparfums (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPAR#NASDAQ">IPAR</a>), presenting a wide array of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Interparfums, revealing an average target of $164.25, a high estimate of $172.00, and a low estimate of $155.00. This current average has decreased by 0.22% from the previous average price target of $164.62. 
<img src="https://www.benzinga.com/files/images/story/2024/1733252423_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The analysis of recent analyst actions sheds light on the perception of Interparfums by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$163.00</td>
<td>$163.00</td>
</tr>
<tr>
<td>Korinne Wolfmeyer</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$155.00</td>
<td>$158.00</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$163.00</td>
<td>$163.00</td>
</tr>
<tr>
<td>Hamed Khorsand</td>
<td>BWS Financial</td>
<td>Maintains</td>
<td>Buy</td>
<td>$172.00</td>
<td>$172.00</td>
</tr>
<tr>
<td>Hamed Khorsand</td>
<td>BWS Financial</td>
<td>Maintains</td>
<td>Buy</td>
<td>$172.00</td>
<td>$172.00</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$163.00</td>
<td>$163.00</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$163.00</td>
<td>$163.00</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$163.00</td>
<td>$163.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Interparfums. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Interparfums compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Interparfums's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Interparfums's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/IPAR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Interparfums analyst ratings.</a>
<h2>Discovering Interparfums: A Closer Look</h2>
Interparfums Inc operates in the fragrance business and produces and distributes a wide array of prestige fragrance and fragrance-related products. It sells its product under the brand which includes Boucheron, Coach, Jimmy Choo, Karl Lagerfeld, Kate Spade, Lacoste, Lanvin, Moncler, Montblanc, Rochas and Van Cleef &amp; Arpels. The company operates in two operating segments namely European based operations, SA, and United States based operations.. The group sells its products to department stores, perfumeries, specialty stores, and domestic and international wholesalers and distributors.
<h3>A Deep Dive into Interparfums's Financials</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Interparfums's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 15.4% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Staples sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 14.66%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Interparfums's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 8.33% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 4.38%, the company showcases effective utilization of assets.
Debt Management: Interparfums's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.28.
<h2>What Are Analyst Ratings?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

IPAR

Analyst Ratings For Interparfums

DoorDash's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NYSE">DASH</a>) short percent of float has risen 4.14% since its last report. The company recently reported that it has 11.63 million shares sold short, which is 3.02% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.63 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>DoorDash Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733252423_0_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for DoorDash has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing DoorDash's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, DoorDash's peer group average for short interest as a percentage of float is 9.96%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

DASH

Peering Into DoorDash's Recent Short Interest

Monster Beverage's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MNST#NYSE">MNST</a>) short percent of float has fallen 3.63% since its last report. The company recently reported that it has 20.05 million shares sold short, which is 2.92% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.55 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Monster Beverage Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733252417_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Monster Beverage has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Monster Beverage's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Monster Beverage's peer group average for short interest as a percentage of float is 7.62%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

MNST

How Is The Market Feeling About Monster Beverage?

Throughout the last three months, 39 analysts have evaluated Walmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>), offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">13</td>
<td align="right">25</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">8</td>
<td align="right">15</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $94.69, with a high estimate of $105.00 and a low estimate of $85.00. This current average has increased by 9.32% from the previous average price target of $86.62. 
<img src="https://www.benzinga.com/files/images/story/2024/1733252416_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A comprehensive examination of how financial experts perceive Walmart is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Greg Melich</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$96.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Seth Sigman</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Mark Astrachan</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$89.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Bill Kirk</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Buy</td>
<td>$97.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Simeon Gutman</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$100.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>Robert Ohmes</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$105.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Scot Ciccarelli</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$98.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>Edward Kelly</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$96.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Greg Melich</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$94.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>Michael Lasser</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Dean Rosenblum</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Outperform</td>
<td>$102.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Steven Shemesh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$96.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Robert Drbul</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Corey Tarlowe</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$105.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Oliver Chen</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Bradley Thomas</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$96.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Peter Benedict</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$100.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$100.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$100.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Peter Keith</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$93.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Kelly Bania</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$100.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Corey Tarlowe</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$92.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Simeon Gutman</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$89.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Bradley Thomas</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$88.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>Edward Kelly</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Robert Drbul</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$90.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Bradley Thomas</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$87.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Greg Melich</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$85.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Dean Rosenblum</td>
<td>Bernstein</td>
<td>Announces</td>
<td>Outperform</td>
<td>$95.00</td>
<td>-</td>
</tr>
<tr>
<td>Rupesh Parikh</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$90.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Bradley Thomas</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$86.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Michael Lasser</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$92.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Joe Feldman</td>
<td>Telsey Advisory Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$92.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Peter Benedict</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$90.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Paul Lejuez</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$98.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Scot Ciccarelli</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$89.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Karen Short</td>
<td>Melius Research</td>
<td>Announces</td>
<td>Buy</td>
<td>$95.00</td>
<td>-</td>
</tr>
<tr>
<td>Edward Kelly</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$88.00</td>
<td>$81.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Walmart. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Walmart compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Walmart's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Walmart's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/WMT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Walmart analyst ratings.</a>
<h2>Unveiling the Story Behind Walmart</h2>
Walmart serves as the preeminent retailer in the United States, with its strategy predicated on superior operating efficiency and offering the lowest priced goods to consumers to drive robust store traffic and product turnover. Walmart augmented its low-price business strategy by offering a convenient one-stop shopping destination with the opening of its first supercenter in 1988.Today, Walmart operates over 4,600 stores in the United States (5,200 including Sam's Club) and over 10,000 locations globally. Walmart generated over $440 billion in domestic namesake sales in fiscal 2024, with Sam's Club contributing another $86 billion to the company's top line. Internationally, Walmart generated $115 billion in sales. The retailer serves around 240 million customers globally each week.
<h3>Understanding the Numbers: Walmart's Finances</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Walmart's revenue growth over a period of 3 months has been noteworthy. As of 31 October, 2024, the company achieved a revenue growth rate of approximately 0.15%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Staples sector.
Net Margin: Walmart's net margin is impressive, surpassing industry averages. With a net margin of 2.7%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Walmart's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 5.31%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Walmart's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.77%, the company showcases efficient use of assets and strong financial health.
Debt Management: Walmart's debt-to-equity ratio is below the industry average. With a ratio of 0.7, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Landscape: 39 Takes On Walmart

BOK Financial's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOKF#NYSE">BOKF</a>) short percent of float has fallen 19.13% since its last report. The company recently reported that it has 238 thousand shares sold short, which is 0.93% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.36 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>BOK Financial Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733252412_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for BOK Financial has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing BOK Financial's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, BOK Financial's peer group average for short interest as a percentage of float is 3.49%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

BOKF

How Is The Market Feeling About BOK Financial?

WIIM

Bank of Nova Scotia shares are trading lower after the company reported worse-than-expected FY24 financial results.

FedEx shares are trading lower after Bernstein downgraded the stock from Outperform to Market Perform and cut its price target from $337 to $316.

Marvell Technology Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) will be reporting its third-quarter earnings on Tuesday. Wall Street expects 41 cents in EPS and $1.46 billion in revenues as the company reports<a href="https://www.benzinga.com/calendars/earnings?tickers=MRVL" target="_blank" rel="noreferrer noopener"> after market hours</a>.
The stock is up 86.35% over the past year, 42.09% over the past six months.
Let&#8217;s look at what the charts indicate for Marvell stock and how the stock currently maps against Wall Street estimates.
Read Also: <a href="https://www.benzinga.com/analyst-ratings/price-target/24/12/42294758/marvell-technology-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call">Marvell Technology Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a>
<h2 class="wp-block-heading">Marvell Stock Chart In Strong Bullish Momentum Ahead Of Q3 Earnings&nbsp;</h2>
Marvell stock is exhibiting strong bullish momentum, supported by technical indicators. 
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent120324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="628" height="490" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03123438/Screenshot-2024-12-03-at-10.57.36-PM.png" alt="" class="wp-image-675002" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03123438/Screenshot-2024-12-03-at-10.57.36-PM.png 628w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/03123438/Screenshot-2024-12-03-at-10.57.36-PM-300x234.png 300w" sizes="(max-width: 628px) 100vw, 628px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent120324&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
The stock&#8217;s price of $96.74 is comfortably above its five, 20, and 50-day exponential moving averages, signaling a robust upward trend. The eight-day simple moving average at $93.40, 20-day SMA at $91.72 and 50-day SMA at $83.14 all confirm a bullish trajectory.
Additionally, MRVL's price is significantly above the 200-day SMA of $73.05, reinforcing its long-term strength. The MACD indicator at 3.15 points to sustained upward momentum, while an RSI (relative strength index) of 66.92 suggests the stock is approaching overbought territory but remains in bullish control.
<h2 class="wp-block-heading">Marvell Analysts See 17% Upside</h2>
Marvell Ratings &amp; Consensus Estimates:<a href="https://www.benzinga.com/quote/MRVL/analyst-ratings" target="_blank" rel="noreferrer noopener"> The consensus analyst rating</a> on Marvell stock stands at a Buy with a price target of $93.88. The latest analyst ratings from Evercore ISI, Susquehanna, and Oppenheimer imply a 17.35% upside for Marvell Technology with an average price target of $114.
MRVL Price Action: Marvell stock was down 0.7% at $96.08 at the time of publication Tuesday.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42282669/sp-nasdaq-settle-at-record-highs-as-tesla-shares-surge-investor-sentiment-decreases-but-fear-greed-index-remains-in-greed-zone">S&amp;P, Nasdaq Settle At Record Highs As Tesla, SMCI Surge: Fear Index Remains In &#8216;Greed&#8217; Zone</a></li>
</ul>
Photo: Shutterstock

Technicals

Previews

Tech

MRVL

Marvell Stock Builds Momentum Ahead Of Q3 Earnings

Stilwell Activist Investments, L.P. (together with its affiliates, "Stilwell"), one of the largest stockholders of IF Bancorp, Inc. ("IROQ" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IROQ#NASDAQ">IROQ</a>), today issued the following statement in connection with the Company's 2024 Annual Meeting of Stockholders:
At last week's Annual Meeting, stockholders approved our Proposal by a 3:2 margin calling for a prompt sale of IF Bancorp, Inc. Although the Proposal is non-binding, IROQ's stockholders agree that the Company should be sold promptly. We urge IROQ's Board of Directors to&nbsp;act now.
If the stockholder-approved Proposal does not lead to the Company's prompt sale, we intend to seek board representation at IROQ's 2025 annual meeting of stockholders.
The Proposal is copied directly below:
Proposal: RESOLVED, that the stockholders of IF Bancorp, Inc. (the "Company" or "IROQ") hereby recommend that the Board of Directors take all necessary steps to promptly effectuate a sale of the Company.
As set forth in our Supporting Statement included in IROQ's proxy statement filed with the Securities and Exchange Commission on October 16, 2024, we believe that the returns on the Company's assets have been subpar for many years and that IROQ stockholders would be best served if the Company and its assets were sold at the earliest opportunity for the highest price available. The Proposal was submitted pursuant to Rule 14a-8 of the Securities Exchange Act of 1934, as amended.

Management

IROQ

Stockholders Approve Stilwell Activist Investments Proposal To Sell IF Bancorp; Says 'If The Stockholder-Approved Proposal Does Not Lead To The Company's Prompt Sale, We Intend To Seek Board Representation At IROQ's 2025 Annual Meeting Of Stockholders'

<a href="https://www.benzinga.com/topic/nebraska-cannabis">Nebraska's</a> Government is fighting cannabis reform both at the local and federal level.
State Attorney General Mike Hilgers recently filed an amended cross-claim on behalf of Secretary of State Bob Evnen in a lawsuit challenging <a href="https://www.benzinga.com/markets/cannabis/24/11/41764503/nebraska-says-yes-to-medical-cannabis-after-years-of-failed-legalization-attempts-heres-what-you">two successful</a> medical cannabis measures.
This move formally introduces new allegations of circulator fraud and widespread malfeasance. The case is moving forward after Lancaster County District Judge Susan Strong ruled in favor of the cannabis ballot sponsors.
Strong dismissed the claims last week, affirming that the medical cannabis petitions met all constitutional and statutory requirements. Yet, Nebraska's leadership is showing no signs of backing down. Regarding the additions, Hilgers <a href="https://nebraskaexaminer.com/briefs/attorney-generals-office-preparing-for-nebraska-medical-cannabis-lawsuit-appeal/">told</a> The Nebraska Examiner that the legal team was merely "taking advantage&#8221; of court rules to prepare for an appeal.
Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you&#8217;re serious about the business, you can&#8217;t afford to miss out.
<h3 class="wp-block-heading">Nebraska's Legal Opposition Goes National</h3>
Being one of the few remaining states where medical cannabis remains illegal, Nebraska's defiance is no longer just a state-level issue. In fact, the Attorney General's Office is the only one of its kind represented at the <a href="https://www.benzinga.com/24/12/42270539/dea-live-hearing-on-marijuana-rescheduling-what-to-expect">DEA hearing on marijuana rescheduling</a> hearings where opposing groups are discussing moving marijuana from a Schedule I to a Schedule III substance under the Controlled Substances Act (CSA).
The prohibitionist group <a href="https://www.benzinga.com/government/regulations/24/11/42198793/prohibitionist-group-denies-collusion-allegations-ahead-of-dea-cannabis-rescheduling-hearing">Smart Approaches to Marijuana </a>(SAM), with whom the AG of Nebraska shares representation are on the opposite side of rescheduling marijuana. 
GOP Governor Jim Pillen and Hilgers frame cannabis reform as a moral and safety issue.
In July 2024, during the <a href="https://www.benzinga.com/markets/cannabis/24/07/39932698/deas-call-for-public-input-on-cannabis-garnered-42-000-comments-majority-want-total-legalization">public comment</a> period of marijuana rescheduling evaluation, Hilgers and 19 Attorneys General from different states presented a letter where they emphasized the national and international ramifications of rescheduling marijuana, particularly concerning international drug treaties and medical cannabis use.
They <a href="https://www.regulations.gov/comment/DEA-2024-0059-41066">claim</a> &#8220;rescheduling marijuana as a Schedule III drug is likely the most consequential rule-making DEA has ever undertaken.&#8221;
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/11/41764503/nebraska-says-yes-to-medical-cannabis-after-years-of-failed-legalization-attempts-heres-what-you">Nebraska Says Yes To Medical Cannabis After Years Of Failed Legalization Attempts: Here&#8217;s What You Need To Know</a>
<h3 class="wp-block-heading">Nebraska's Growing Isolation On Cannabis</h3>
While other states, including neighboring&nbsp;Missouri&nbsp;and&nbsp;South Dakota, have legalized medical cannabis, Nebraska remains one of the few holdouts. 
Now the state GOP is fighting against approved ballots, which they&#8217;ve lost on their first round.
Thus Nebraska is increasingly isolated, with national trends shifting toward legalization and decriminalization. Still, much of the rollout of medical marijuana programs will depend on the willingness of authorities to move forward with regulations.
In a state with a single legislative chamber and a history of conservative governance, it's uncertain what will happen if the state chooses not to appeal the judge's ruling on the <a href="https://www.benzinga.com/markets/cannabis/24/11/41764503/nebraska-says-yes-to-medical-cannabis-after-years-of-failed-legalization-attempts-heres-what-you">approved cannabis ballots</a>, particularly when it comes time to establish the terms for medical cannabis.
Read Next: <a href="https://www.benzinga.com/24/12/42270539/dea-live-hearing-on-marijuana-rescheduling-what-to-expect">DEA LIVE Hearings On Marijuana Rescheduling, What To Expect</a>
Cover: Benzinga edit using Mike Hilgers media website + Tinakru via Pixabay

Cannabis

Government

Regulations

Politics

Nebraska's Two-Front War On Cannabis

INTC

Intel shares are trading lower. The stock has been volatile after the company on Monday announced the retirement of CEO Pat Gelsinger.

Goldman Sachs hosted a meeting with Pfizer Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) newly appointed Chief Scientific Officer Chris Boshoff (effective January 1, 2025).
The analyst maintains the Buy rating with a <a target="_blank" href="https://www.benzinga.com/quote/PFE/analyst-ratings" rel="noreferrer noopener">price target of $33</a>.
When discussing core capabilities at Pfizer, the commentary highlighted a strategic shift toward prioritizing efforts. The focus will be on opportunities expected to deliver the highest economic returns while maintaining a balanced portfolio of high-risk <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41274121/whats-going-on-with-pfizer-stock-on-thursday" rel="noreferrer noopener">and low-risk projects</a>.
With an annual R&amp;D budget of about $11-12 billion—representing roughly a high-teens percentage of revenue—the company plans to allocate resources to key areas such as Oncology and reaffirmed its commitment to programs targeting obesity, cardiovascular, and metabolic diseases.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/11/42013119/whats-going-on-with-large-european-and-us-vaccine-makers" rel="noreferrer noopener">European And US Vaccine Stocks Are Under Pressure &#8211; Here&#8217;s Why</a>
The analyst notes that Boshoff believes the anti-obesity medicine market is still in its early stages. He envisions a future in which the market is segmented based on factors like co-morbidities, different treatment mechanisms, delivery methods (Pfizer focuses on oral delivery), and combination therapies <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39753273/with-oral-anti-obesity-candidate-development-pfizer-seeks-relevant-and-competitive-" rel="noreferrer noopener">playing crucial roles</a>.
Boshoff told the analyst that anti-obesity medicines are expected to become more integrated into primary care. He highlighted Pfizer&#8217;s strong history with widely used medications like Lipitor and Eliquis, suggesting this experience aligns with their strategic goals.
Among Pfizer&#8217;s three clinical-stage anti-obesity programs, Boshoff expressed confidence in one molecule potentially being among the first oral GLP-1/AOMs available in the U.S. market.
Goldman Sachs adds that Pfizer sees Comirnaty and Paxlovid as reliable long-term products. The company expects steady demand due to ongoing COVID-19 mutations. The company anticipates more stable vaccination rates and improved commercial stability overall.
In the third quarter, the U.S. drugmaker reported sales of $17.70 billion, up 31% year-over-year (up 32% operationally), <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41596761/pfizer-q3-earnings-revenue-and-profit-on-heightened-demand-for-paxlovid-expects-10-billion-in-202" rel="noreferrer noopener">beating the&nbsp;consensus of $14.95 billion</a>.
The increase was primarily led by growth contributions from Paxlovid and several acquired products, key in-line products, and&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/b41594926/pfizer-reports-strong-third-quarter-2024-results-and-raises-2024-guidance" rel="noreferrer noopener">recent commercial launches</a>.
Regarding its COVID-19 and influenza combination vaccine, Pfizer remains optimistic about its market potential and is testing new formulations to overcome challenges <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40416914/pfizer-biontechs-covid-19flu-combo-vaccine-fails-to-meet-key-goal-in-late-stage-study" rel="noreferrer noopener">from earlier clinical data</a>.
Pfizer recognizes setbacks in its immunology pipeline but remains committed and plans to focus on advancing select early-stage pipeline projects.
Price Action: PFE stock is down 0.77% at $25.62 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42297870/keros-therapeutics-licensing-deal-with-takeda-aligns-with-broader-opportunity-for-elritercept-analyst" target="_blank" rel="noreferrer noopener">Keros Therapeutics&#8217; Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst</a></li>
</ul>
Image via Shutterstock.

Analyst Color

Equities

Pfizer's New Chief Scientific Officer Charts R&D Vision For High And Low-Risk Investments

Graphjet Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTI#NASDAQ">GTI</a>) shares are trading higher on Tuesday after the company announced that it has achieved key breakthroughs in <a href="https://www.benzinga.com/markets/commodities/24/12/42287394/exclusive-graphjet-technology-pilot-testing-accomplishes-99-99-graphite-purity-and-98-8-graphitization">producing synthetic graphite.</a>
The Details: The company has produced synthetic graphite, named artificial green graphite, with a purity level of 99.9% and a graphitization level of 98.8%.
Graphjet&#8217;s green graphite is produced using palm-based biomass residues, an agricultural waste product. This process contributes to sustainability by utilizing waste materials and reducing the carbon footprint of graphite production compared to traditional methods.
The company&#8217;s technology generates 2.95 kg of CO2 emissions, lower than the 16.8 kg and 17 kg emissions produced by natural and synthetic graphite production in China, respectively.
&#8220;These results verify that our patented technology is mature and reliable and that we are committed to providing industry-leading artificial graphite products to global customers, backed by proven metrics that they can trust,&#8221; said Aiden Lee, CEO and Co-Founder of Graphjet.
&#8220;These significant innovations further validate our technology as we position ourselves as the world&#8217;s leading supplier of green graphite.&#8221;
Related Link: <a href="https://www.benzinga.com/insights/options/24/12/42298019/uber-technologies-options-trading-a-deep-dive-into-market-sentiment">Uber Technologies Options Trading: A Deep Dive into Market Sentiment</a>
GTI Price Action: At the time of writing, Graphjet stock is trading 26.3% higher at $3.17, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: Image via Pexels

Movers

What's Going On With Graphjet Stock Tuesday?

<a href="https://x.com/CitronResearch/status/1864018794873495945" title="https://x.com/CitronResearch/status/1864018794873495945">https://x.com/CitronResearch/status/1864018794873495945</a>

NBIS

Citron Research Posts On X "Citron pounding the table that $NBIS is poised to be the next AI Wall Street darling. A sleeper with no analyst coverage yet, the market hasn't caught on to its massive potential—or its undervaluation vs. CoreWeave.   If it trades at a 50% discount to Coreweave multiple that puts $NBIS at $60 (napkin math)...."

<a href="https://www.chicagofed.org/events/2024/ag-conference" title="https://www.chicagofed.org/events/2024/ag-conference">https://www.chicagofed.org/events/2024/ag-conference</a>

Macro Economic Events

Economics

Federal Reserve

Fed's Goolsbee Says Inflation Data Is A Noisy Series; Over Next Year, Rates Should Come Down A Fair Amount From Where They Are Now; My Belief That Rates Will And Should Come Down Is Rooted In Read That Inflation Is Coming Down

Analyst Robert Moskow of TD Cowen maintained a Buy rating on BellRing Brands (BRBR – Research Report), with a price target of $83.00. Robert Moskow...

Strong Financial Performance and Market Leadership Drive Buy Rating for BellRing Brands

Jefferies raised the firm's price target on BellRing Brands (BRBR) to $86 from $84 and keeps a Buy rating on the shares. The firm said that the com...

BellRing Brands price target raised to $86 from $84 at Jefferies

These 19 stocks are poised for tax reform turbocharge - Jefferies

Barclays raised the firm's price target on BellRing Brands (BRBR) to $79 from $74 and keeps an Overweight rating on the shares. The company has pre...

BellRing Brands price target raised to $79 from $74 at Barclays

In a report released on November 19, Kenneth Goldman from J.P. Morgan maintained a Buy rating on BellRing Brands (BRBR – Research Report), with a p...

J.P. Morgan Remains a Buy on BellRing Brands (BRBR)

Franklin Small Cap Growth Fund Q3 2024 Commentary

Stephens analyst Jim Salera raised the firm's price target on BellRing Brands (BRBR) to $75 from $61 and keeps an Equal Weight rating on the shares...

BellRing Brands price target raised to $75 from $61 at Stephens

SA quant grades ranks 20 JPMorgan overweight consumer stock picks

JPMorgan updates its U.S. Analyst Focus List – Adds TPR, ALRM, REG

BellRing Brands: Half-Time Adjustments To Secure The Lead

ABBV

AGCO

ALGT

ALRM

AMZN

ARMK

ASND

AVGO

BASE

BFAM

BRBR

BWXT

CAVA

CVNA

CYBR

DAWN

DELL

DKNG

ENVA

EWTX

FRPT

GMED

GWRE

INSP

ISRG

ITGR

KLAC

KVUE

LEGN

LPLA

MNDY

MSFT

MTDR

NTRA

ONTO

PFGC

PLMR

PODD

POST

ROIV

RVMD

SCHW

SIRI

SITE

SITM

SNDX

SPGI

SWTX

TFII

TMUS

TRGP

TVTX

ULTA

VERA

VICI

WING

XENE

Earnings

Press Releases

BellRing Brands Reports Results for the First Quarter of Fiscal Year 2024; Raises Fiscal Year 2024 Outlook

Restaurants

General

Sports Nutrition Market Size Expected to Reach $81 Billion by 2030 as Workout Nutritional Supplements Demand Rises

BellRing Brands Announces New Share Repurchase Authorization of $300 Million

BellRing Brands Schedules Second Quarter Fiscal Year 2024 Conference Call

BellRing Brands Reports Results for the Second Quarter of Fiscal Year 2024; Raises Fiscal Year 2024 Outlook

Global Sports Nutrition Market Projected to Reach $78 Billion as Muscle Repair & Growth Becoming Vitally Important

BellRing Brands Schedules Third Quarter Fiscal Year 2024 Conference Call

BellRing Brands Reports Results for the Third Quarter of Fiscal Year 2024; Raises Fiscal Year 2024 Outlook

BellRing Brands Schedules Fourth Quarter Fiscal Year 2024 Conference Call

BellRing Brands Reports Results for the Fourth Quarter and Fiscal Year 2024

CELH

COKE

CSE:MUSL

MUSLF

Coty

Big Tree Cloud Holdings Limited - Ordinary Shares

Big Tree Cloud Holdings

Estee Lauder Companies, Inc. (The) Common Stock

Estee Lauder Cos

e.l.f. Beauty

Edgewell Personal Care Company Common Stock

Edgewell Personal Care

FitLife Brands

Herbalife

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Honest Co

Interparfums

Kenvue

Lifevantage

Medifast

Nature's Sunshine Products, Inc. - Common Stock

Natures Sunshine Products

Natural Health Trends Corp. - Commn Stock

Natural Health Trends

Nu Skin Enterprises

Olaplex Hldgs

Paranovus Entertainment Technology Ltd. - Class A Ordinary Shares

Paranovus Enter

Safety Shot

The Beauty Health Company - Class A Common Stock

Beauty Health

Unilever

Usana Health Sciences

Veru

Waldencast

Yatsen Holding Limited American Depositary Shares, each representing twenty (20) Class A Ordinary Shares

Yatsen Holding

Stephens & Co.

Barclays

Truist Securities

Comments

BellRing Brands

ニュース

最新ニュース BellRing Brands (NYSE:BRBR) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル